Navigating treatment resistance:Janus kinase inhibitors for ulcerative colitis  

作　　者：Jonathan Soldera 

机构地区：[1]Acute Medicine and Gastroenterology,University of South Wales,Cardiff CF371DL,United Kingdom

出　　处：《World Journal of Clinical Cases》2024年第24期5468-5472,共5页世界临床病例杂志

摘　　要：The management of refractory ulcerative colitis(UC)and acute severe UC(ASUC)is challenging due to the lack of standardized approaches in cases resistant to multiple treatments.In this editorial,I investigate the efficacy and safety of Janus kinase inhibitors,particularly upadacitinib and tofacitinib,in controlling severe and refractory disease.I highlight a notable case report by Xu et al,which explores the case of a patient with primary nonresponse to two classes of biologics and two fecal microbiota transplants who exhibited a remarkable response to upadacitinib.Furthermore,I discuss the use of tofacitinib in refractory UC and ASUC,either as monotherapy or in combination with biologics,which has shown promising response rates.Additionally,emerging evidence of upadacitinib efficacy in ASUC is presented.Overall,these cases emphasize the complex nature of managing refractory ASUC and the potential of small-molecule therapies to achieve remission.Further research is needed to refine treatment strategies for patients with treatment-resistant UC.

关 键 词：Inflammatory bowel disease Ulcerative colitis Janus kinase inhibitor Upadacitinib Tofacitinib INFLIXIMAB 

分 类 号：R574.62[医药卫生—消化系统] R558.2[医药卫生—内科学]